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ABSTRACT 
Benzodiazepines are effective pharmaceutical agents used to alleviate 
insomnia, anxiety, muscle tension and mild epileptic seizures; however, side effects 
such as increased appetite often deter long-term use of these compounds. 
Benzodiazepines act at multiple receptor sites and it has been suggested that the 
effects of these compounds may be related to their activity at specific receptor 
subtypes. An important focus of pharmacological research is to elucidate behavioral 
properties mediated by each receptor subtype in order to enable the development of 
compounds that retain therapeutic properties but have reduced unwanted side effects. 
The present study sought to determine the involvement of GABAA receptors 
containing the a 1 subunit (i.e., GABAA/a1 receptor) in the appetite-enhancing effects 
(i.e., hyperphagia) ofbenzodiazepines. Zolpidem, a GABAA/a1-preferring agonist, 
and t.riazolam, a nonselective benzodiazepine agonist, were evaluated for their abi lity 
to induce a hyperphagic effect. Five squirrel monkeys received var yi ng doses of 
uiazolam (0.003 - 0.3 mg/kg) and zolpidem (0.3 - 17.8 mg/kg). All monkeys 
demonstrated an increase in feeding behavior compared to baseline intake. To further 
assess the role of GABAA/a.1 receptors in the hyperphagic effects of benzodiazepines, 
the effects of triazolam and zolpidem were re-determined fo llowing pre-treatments 
with varying doses of a nonselective benzodiazepine antagonist, fl umazenil (0.003 -
10.0 mg/kg), and a GABAA/a.1-preferring antagonist, ~-CCt (0.03 - 10.0 mg/kg). 
Flumazeni l antagonized tri azolam- and zolpidem-induced hyperphagia, suggesting 
this effect is mediated by benzodiazepine receptors. ~-CCt also blocked the increase 
in food intake induced by tri azolam and zo lpidem, suggesting GABAA/a,1 receptors 
play an important role in mediating benzodiazepine-induced hyperphagia. F uture 
pharmaceutical development of benzodiazepine compounds potentially should 
concentrate efforts to synthes ize compounds with reduced activity at GABAA/a,1 
receptors, in order to reduce the unwanted side effect of hyperphagia. 
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I. Early Development of Se~ative-Anxiolytics 
In 1864, Adolf von Baeyer first synthesized barbituric acid from malonic acid 
and urea, which subsequently led to the development of a class of drugs now known 
as barbiturates (Palfai & J ankiewicz, 1997). This new class of drugs displayed 
sedative 1, hypnotic2, anticonvulsant, and anesthetic behavioral properties and were 
consequently prescribed for over seventy psychiatric disorders throughout the 
twentieth century. The first barbiturate synthesized was barbital in 1882, followed by 
the commonly-used compounds phenobarbital, pentobarbital and nearly 2,500 other 
barbiturates (McKim, 1997). 
Barbiturates exhibit effects similar to those of ethanol and were prescribed as 
sedative-anxiolytics3 (Pies, 1998; Snyder, 1986). Short-acting barbiturates were used 
as general anesthetics and in the treatment of insomnia, while long-acting compounds 
were used to treat anxiety disorders, such as generalized anxiety disorder and panic 
disorder. While barbiturates are safer than alcohol, they can be lethal at high doses or 
when combined with alcohol, and were found to produce dependence and withdrawal. 
When used to treat insomnia, barbiturates can interrupt REM (rapid eye movement) 
sleep and produce residual effects manifested as daytime drowsiness, clumsiness, and 
loss of motivation (Carvey, 1998; Palfai & Jankiewicz, 1997). Virtually all sedative-
anxiolytics have the ability to alleviate anxiety; however, the dose required to achieve 
this effect usually induces sedation. Consequently, intensive efforts to identify 
compounds that reduce anxiety without inducing sedation have been a major focus of 
pharmaceutical development since the 19th century. 
2 
Based on the development and use of chlorpromazine as a drug to treat 
psychiatric disorders in the mid-l 950s, Leo Stembach, a chemist at Hoffman-
LaRoche Laboratories, synthesized approximately 40 compounds referred to as 
quinazolines (Perrine, 1996). All but one of these compounds were evaluated using 
behavioral measures and were shown to be devoid of relevant behavioral effects. 
Consequently, the project was abandoned. However, in 1957, the last compound was 
submitted for behavioral testing as a result of routine laboratory cleaning (Palfai & 
Jankiewicz, 1997). The compound was shown to have anxiolytic, anticonvulsant, 
muscle relaxant, sedative and appetite-stimulating effects (Randall, Schallek, Heise, 
Keith, & Bagdon, 1960). The latter compound was named chlordiazepoxide and after 
additional behavioral testing, was marketed as Librium®, the first benzodiazepine 
(Palfai & Jankiewicz, 1997). 
Stembach followed this success with the development of diazepam 
(Valium®), which became the most prescribed drug of any kind after its introduction 
in 1963 (Palfai & Jankiewicz, 1997). Since their discovery, over 3,000 
benzodiazepines have been synthesized and approximately 15 benzodiazepine 
compounds are currently in clinical use in the United States (Grilly, I 998; Palfai & 
Jankiewicz, 1997). Alprazolam (Xanax®) has recently replaced diazepam as the 
most prescribed anxiolytic (Grilly, 1998). 
Benzodiazepines used as sedative-anxiolytics are safe, long-acting drugs that 
are useful clinically as hypnotics, anxiolytics, muscle relaxants and anticonvulsants. 
However, acute and chronic administration ofbenzodiazepines can result in harmful 
side effects that have hindered their usefulness as therapeutic agents. In this regard, 
benzodiazepine administration is associated with the potential for tolerance, 
dependence, withdrawal effects, and memory impairment (Ashton, 1991; Griffiths & 
Weerts, 1997; Lader, 1995; Marin, Salvatierra, & Ramirez, 1996; Mintzer & 
Griffiths, 1999): In addition, a number of clinically useful benzodiazepines have 
been reported to induce hyperphagia (see Table I). This increase in food 
consumption can be detrimental to an individual's treatment, potentially causing 
health problems related to weight gain and hindering compliance (Menkes, 1992; 
Schenck, Hurwitz, Bundlie, & Mahowald, 1991). 
II. GABAA Receptors and Benzodiazepine Action 
While benzodiazepines have been used extensively since their introduction in 
the 1960s, their specific action at the molecular level was, at the time, unknown. In 
the l 970's, researchers discovered that the mechanisms of action ofbenzodiazepines 
involved the neurotransmitter gamma-aminobutyric acid (GABA), the major 
inhibitory neurotransmitter in the nervous system (Snyder, 1986). In 1977, specific 
benzodiazepine receptor sites were found on GABA receptors. This discovery of 
benzodiazepine receptor sites gave rise to a neurochemical basis for anxiety, as well 
as the effects of benzodiazepines in the central nervous system. Subsequent research 
found that benzodiazepines do not compete with GABA, but rather enhance the 




While GABAA, GABAa and GABAc receptors have been identified in the 
mammalian nervous system, benzodiazepines act only at GABAA receptors (Sieghart, 
1995). GABAA receptors are pentameric membrane proteins composed of five 
subunits that constitute a chloride ion channel (see Figure 1). When stimulated by 
GABA, the chloride channel opens to allow ,an inflow of chloride into the neuron 
resulting in hyperpolarization. In the presence of GABA, benzodiazepine agonists 
exert their action by binding to a specific recognition site on the GABAA receptor and 
allosterically modulating5 the efficiency of GABA (Luddens, Korpi, & Seeburg, 
1995; Sanger et al., I 994). By increasing the frequency in which the chloride 
ionophore opens, benzodiazepines enhance the amplitude of miniature inhibitory 
postsynaptic currents (mIPSC) caused by the increase in chloride concentration in the 
neuron (Mohler, Fritschy & Rudolph, 2002). The enhancement ofmIPSCs decreases 
the likelihood that the postsynaptic cell will fire, resulting in greater inhibition of the 
postsynaptic neuron. Because benzodiazepines do not produce pharmacological 
action without the presence of GABA, they are a safer class of compounds compared 
to barbiturates, which have the ability to stimulate GABAA receptors at high doses 
without the presence of GABA (Sieghart, 1995). 
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Figure I 
GABA, benzodiazepines, and barbiturates bind to the GABA,1 receptor, a pentamer of 
five subunit proteins constituting a chloride ion channel. 
GABAA Receptor 
Of the subunit classes that have been identified, GAB AA receptors typically 
consist of two a, two ~, and one y subunit (Pritchett et al., 1989; Rudolph, Crestani, 
& Mohler, 2001). Receptors containing these subunits are sensitive to 
benzodiazepines; however, the a subunit seems to determine the benzodiazepine 
pharmacology of the receptor (Doble & Martin, 1992; Pritchett et al., 1989). For 
example, receptors containing the a1 subunit (GABAA/a1 receptors) are sensitive to 
zolpidem, zaleplon and CL 218,872; .however, these compounds have low or no 
affinity6 for GABAA receptors containing a:2, a:3, or as subunits (Atack, Smith, 
Emms, & McKernan, 1999; Doble & Martin, 1992; Noguchi, Kitazumi, Mori, & 
Shiba, 2002; Sieghart, 1995). 
6 
While GABAA receptor subunits are ubiquitous throughout the central 
nervous system, particular subunits tend to cluster in certain regions (McKernan & 
Whiting, 1996). GABAA/a:1 receptors account for approximately 43% of all GABAA 
receptors and are localized to interneurons in most brain regions. GABAA/a:2 
receptors are found in the spinal cord and limbic system and constitute approximately 
26% of GABAA receptors. While GABAA/a:3 receptors are found predominately in 
the cerebellum and spinal cord (I 7%), GABAA/a:5 receptors only account for 4% of 
GABAA receptors and are found primarily in the hippocampus. This differential 
distribution suggests that distinct subtypes may mediate various actions of 
benzodiazepines. For example, a high concentration of GABAA/a:1 receptors in the 
cerebellar cortex suggests these receptors are involved in the motor-impairing effects 
ofbenzodiazepines (Rudolph et al., 2001). Likewise, a high concentration of 
GABAA/a:2 receptors in the limbic system suggests these receptors may be linked to 
the addictive properties ofbenzodiazepines, while GABAA/a:5 receptors in the 
hippocampus may mediate the anterograde amnesic effects. Because the 
hypothalamus is involved in eating behavior, the GABAA subunits occupying this 
brain region may be involved in the hyperphagic effect ofbenzodiazepines. 
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III. Mediation of Benzodiazepine Effects by GABAA Receptor Subtypes 
The diverse behavioral effects of benzodiazepines are thought to be mediated 
through varying affinities and stimulation of specific GABAA receptor subunits 
(Mohler et al., 2002; Rudolph et al., 200 I). Recently, genetically altered mice have 
been used to evaluate the behavioral effects associated with GABAA receptor 
subtypes. By rendering specific a subunits insensitive to benzodiazepine receptor 
ligands, evidence has been obtained suggesting GABAA/a1 receptors mediate the 
sedative, motor-impairing and anticonvulsant actions ofbenzodiazepine agonists7, 
while GABAA/a2 receptors mediate the anxiolytic and myorelaxant properties of 
these drugs (Crestani, Martin, Mohler, & Rudolph, 2000; Low et al., 2000; McKernan 
et al., 2000; Rudolph et al., 2001). While research using geneticalfy altered mice 
provides important behavioral information concerning receptor subtypes, this strategy 
also presents complicating factors (Rudolph et al., 2001). For example, genetic 
mutation potentially can cause adaptive changes in neuronal function and can alter the 
expression in neighboring genes that may confound research results and 
interpretations. 
An alternate strategy for studying the behavioral effects associated with 
different GABAA receptor subtypes involves the use of subtype selective compounds 
in non-genetically altered subjects. Investigations based upon this methodology 
provide consistent evidence ofa differential role ofGABAA/a1 and GABAA/a2 
receptors. P-carboline-3-carboxylate-t-butyl ester (P-CCt) is a selective 
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benzodiazepine antagonist8 displaying a 21- and 26-fold selectivity for GABAA/a1 
versus GABAA/a2 and GABAA/a3 receptors, respectively, and 154-fold selectivity for 
GABAA/a1 compared to GABAAl<Xs receptors (Huang et al., 2000). /3-CCt has been 
shown to block some of the effects of the GABAA/a1-preferring agonist zolpidem in 
mice, but not the effects of triazolam, a non-selective benzodiazepine agonist 
(Rowlett, Tornatzky, Cook, Ma, & Miczek, 2001). Moreover, /3-CCt antagonized 
anticonvulsant effects thought to be mediated by GABAA/a1 receptor activity, but 
failed to inhibit the myorelaxant effects ofbenzodiazepine agonists which are 
believed to be associated with GABAA/a2 receptors (Griebel et al., I 999; Shannon, 
Guzman, & Cook, I 984). Through the use of non-genetically altered subjects, these 
conclusions strengthen the interpretations obtained from transgenic mice and provide 
a more comprehensive analysis of GABAA receptor subunit function. 
N. Hyperphagic Effect ofBenzodiazepines 
As noted previously, benzodiazepine administration is associated with 
pronounced appetite enhancing effects. In several experimental studies, diazepam, 
alprazolam, and triazolam increased eating behavior in both naive human volunteers 
and volunteers reporting a history of drng abuse ( e.g., Haney, Comer, Fischman, & 
Fol tin, 1997; Kelly, Foltin, King, & Fischman, I 992). Similarly, a cessation of 
nocturnal bingeing was observed in two case studies following a reduction of 
triazolam administration, suggesting the hyperphagic effect was due to the 
pharmacological effects oftriazolam (Menkes, 1992; Schenck et al., 1991). 
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Consistent with research documenting this enhancement of food intake in 
people, several benzodiazepines have been shown to produce a similar hyperphagic 
effect in animals (see Table 1). However, the mechanisms of action underlying the 
hyperphagic effects of benzodiazepines are not understood completely. The 
nonselective benzodiazepine antagonist flumazenil attenuated the hyperphagic effect 
produced by diazepam, chlordiazepoxde, and midazolam (Cooper & Yerbury, 1986; 
Foltin, Ellis, & Schuster, 1985; Mansbach, Stanley, & Barret, 1984; Sanger & 
Zivkovic, 1988). In addition, benzodiazepine inverse agonists9 that bind to the 
benzodiazepine receptor site but decrease the effects of GABA have been shown to 
induce dose-dependent reductions in food intake (Cooper, Barber, Gilbert, & Moores, 
1985; Cooper & Yerbury, 1986). Because benzodiazepine-induced hyperphagia can 
be attenuated through the co-administration of a benzodiazepine antagonist, and 
inverse agonists suppress food consumption, research thus far suggests 
benzodiazepine receptors are involved in the appetite enhancing effects observed with 
the use ofbenzodiazepines. 
Recent research has revealed that benzodiazepine agonists with preferential 
action at GABAA/a1 receptors also produce a hyperphagic effect (see Table I). 
Although these studies are consistent with the involvement of the GABAA/a1 receptor 
in the hyperphagic effect of benzodiazepines, the available research is not entirely 
consistent. For example, several studies reported no increase in food consumption 
after administration of zolpidem in deprived and non-deprived rats (Sanger & 
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Zivkovic, 1988; Yerbury & Cooper, 1989; Davies et al., 1994). However, others 
have documented a hyperphagic effect following zolpidem administration in baboons 
(Griffiths, Sannerud, Ator, & Brady, 1992; Weerts, Ator, Grach, & Griffiths, 1998). 
Thus, at present, the involvement of specific GABAA subunit(s) in mediating the 
hyperphagic effect ofbenzodiazepine agonists is not clear. 
V. Purpose of the Present Study 
The purpose of this thesis was to further explore the role ofGABAA/a1 
receptors in the hyperphagic effect ofbenzodiazepine agonists. In the present study, 
food intake following administration of triazolam, a prototypical nonselective 
benzodiazepine agonist, was compared to that ofzolpidem, a GABAA/a1-preferring 
agonist. To further characterize the role of GABAA/a1 receptors in the hyperphagic 
effects of benzodiazepine agonists, the effects of triazolam and zolpidem were 
evaluated in the presence of the GABAA/a1-preferring antagonist ~-CCt in 
comparison with antagonism produced by the reference nonselective antagonist 
flumazenil. Due to similarities in genotypes, the use of nonhuman primates will 
facilitate the generalization of these conclusions to humans. Thus, this study sought 
to document the hyperphagic effect in squirrel monkeys following the administration 
of 1) a nonselective benzodiazepine agonisi (triazolam), 2) a GABAJa1-preferring 
agonist (zolpidem), and 3) the combination of each of the agonists with a nonselective 
antagonist, flumazenil, and a GABAA/a,-preferring antagonist, ~-CC!, to examine the 
role of the GABAA/a1 receptors in the hyperphagic effect ofbenzodiazepine agonists. 
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Table I 
Differential Effects of Benzodiazepine-Type Drugs on Food Intake Across Several 
Species 
Effect on 
Nonselective Agonists Food Intake S2ecies Reference 
Triazolam + baboons 1, 2 
Midazolam + n.d. rats 3,4,5 
Clonazepam + n.d. rats 4 
Chlordiazepoxide + rats, rhesus monkeys, 4, 6, 7, I 5 
squirrel monkeys 
Diazepam + rhesus monkeys, squirrel 7,8,9,10 
monkeys, dwarf goats, 
baboons, rabbits 
Brotizolam + dwarf goats, mice 8, 11 
Climazolam + dwarf goats 8 
Flunitrazepam + n.d. rats 12 
Lorazepam + rhesus monkeys 7 
CGS 9896 + n.d. rats 12 
GABAA/o:l-2referring agonists 
CL 218,872 + n.d. rats, squirrel monkeys 4, 16 
Zaleplon + baboons 2 
Quazepam + mice I I 
Zolpidem +/0 baboons, mice, rats I, 6, 11, 
12, 13, 14 
Antagonists and Inverse Agonists 
Flumazenil 0 baboons 3, 10 
f3-CCE 0 rabbits IO 
FG 7142 n.d. rats 3, 5 
DMCM n.d. rats 3 
+, increase; 0, no effect;-, decrease; n.d., non-deprived 
1Griffiths et al., 1992; 2Ator, Weerts, Kaminski, Kautz, & Griffiths, 2000; 3Cooper et 
al., 1985; 4Cooper & Moores, 1985; 5Cooper & Yerbury, 1986; 6Sanger & Zivkovic, 
1988; 7Kumar, Palit, Singh, & Dhawan, 1999; 8 Van Miert, Koot, & Van Duin, 1989; 
9Foltin, Fischman, & Byrne, 1989; IOMansbach et al., 1984; 11Perrault, Morel, Sanger, 
& Zivkovic, 1990; 12Davies et al., 1994; 13Weerts, Ator et al., 1998; 14Yerbury & 




Five adult male squirrel monkeys (Saimiri sciureus), weighing 750 to 950g, 
served as subjects in this study. Sessions were conducted daily between 9 a.m. and 2 
p.m. Monday through Saturday. Between sessions, monkeys were individually 
housed with unrestricted access to food (Teklad Monkey Diet supplemented with 
fresh fruit) and water. Three monkeys had participated in an observational study in 
which the behavioral effects of dopamine receptor ligands were assessed. The 
remaining two subjects were experimentally naive at the start of the present study. 
All animals were maintained in accordance with the guidelines of the Standing 
Committee on Animals of the Harvard Medical School and the "Guide for Care and 
Use of Laboratory Animals" of the Institute of Laboratory Animal Resources, 
National Research Council, Department of Health, Education and Welfare 
Publication No. (NIH) 85-23, revised 1996. Research protocols were approved by the 
Harvard Medical School Institutional Animal Care and Use Committee. 
Drugs 
Triazolam base (Sigma/RBI; St. Louis, MO), zolpidem base (G. Dawson, 
Merck, Sharp & Dohme, Harlow, UK), flumazenil (Hoffman-La Roche, Inc., Nutley, 
NJ) and B-CCt base (J. Cook, University of Wisconsin - Milwaukee) were dissolved 
in small amounts of95% ethanol and 0.IN HCl as required and diluted to the desired 
concentrations with a 50% propylene glycol/50% saline solution. When possible, 
injection volumes were 0.1 ml/kg of body weight. The solubility limitations of 
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zolpidem precluded using the above iajection volume and higher doses ofzolpidem 
( e.g., 10.0 or 17.8 mg/kg) were administered in the smallest volume possible 
depending on the size of the monkey (e.g., approximately 0.4 ml/kg ofbody weight). 
Apparatus 
Studies were conducted in a ventilated, transparent Plexiglas chamber (114 
cm X 122 cm X 213 cm) located in a lighted room isolated from other animals (see 
Figure 2). The chamber was equipped with perches, suspended plastic chains, and a 
wood chip foraging substrate. 
Figure 2 
The observation chamber was isolated from other monkeys and was equipped with 










The monkeys were initially habituated to the observation chamber and the 
haudling and injection procedures described below for a period of approximately one 
month. During this phase, saline was administered five minutes prior to the session, 
and each monkey was placed in the chamber with access to 100 food pellets (Noyes 
Precision Food Pellets, sucrose with fruit punch, 190 mg, Lancaster, NH) for ten 
minutes per day in order to establish baseline levels of food intake. Feeding between 
sessions was not restricted. Drug test sessions were conducted three times per week 
with saline control sessions on intervening days. A full rauge of doses oftriazolam 
(0.003 - 0.3 mg/kg), zolpidem (0.3 - 17.8 mg/kg), flumazeni! (0.003 - I 0.0 mg/kg), 
and P-CCt (0.03 - 10.0 mg/kg) were tested. Pretreatment intervals were chosen on 
the basis ofresults from preliminary studies (triazolam: 60 min, zolpidem: 10 min, 
tlui:nazenil and P-CCt: 40 min, Platt et al., in press). Antagoriism studies were also 
conducted in which selected doses offlumazenil (0.03 and 0.3 mg/kg) and P-CCt (1.0 
and 3.0 mg/kg) were studied in combination with a range of doses oftriazolam and 
zolpidem. All drugs, including saline controls, were administered via intramuscular 
injections in the calf or thigh. Saline and drug test sessions both consisted often 
minute sessions in which I 00 food pellets were available as described above. 
Data Analysis 
Food intake was determined by measuring the number of pellets remaining in 
the food dish and bedding at the completion of the test session. Due to a small 
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number of subjects in the study and subsequent variability, food intake was converted 
to a percentage of control intake for each animal. The number of pellets consumed 
during drug test sessions was divided by the number of pellets consumed during 
preceding saline sessions and multiplied by 100. The percentage of control intake, 
averaged across subjects, was plotted as a function of dose for each drug and drug 
combination (mean±SEM). A one-way repeated measures analysis of variance 
(ANOVA) was computed for each agonist to determine differences between doses. 
To assess observed increases in intake, one-sample !-tests were used to compare the 
mean intake for each dose of agonist and antagonist to 100, which represented control 
intake. A significant difference between the mean intake and control intake indicated 
the corresponding dose produced a reliable change in eating. 
Doses corresponding to 50% of the maximum effect (ED5o) were calculated 
for each animal under all doses of agonists and antagonists using log-linear regression 
analysis. For this analysis, the percentage of control intake that corresponded to half 
of the maximum increase in food intake (Iso) was determined by adding 100 to each 
animal's peak percentage intake (EMAX) for each dose and dividing by two [Iso = 
(EMAX + 100)/2]. This value was used in the generated regression line equation to 
calculate the ED50 for an individual monkey. EDso values for some doses of 
antagonists could not be calculated if the amount of intake corresponding to 50% of 
the maximum effect of the agonist (Iso) was not reached.· EDso values were then 
converted to dose ratios to assess the magnitude of the shift of dose-response curves. 
Dose ratios for each drug condition were calculated by dividing the combined EDso 
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values of the agonist and antagonist by the ED50 value of the agonist alone. The 
magnitude of the shift between each agonist and the two corresponding doses of 
antagonists were assessed by calculating 95% confidence intervals for the dose ratios. 
If the lower and upper confidence interval limits of the corresponding antagonists did 
not overlap, the dose ratios were presumed significantly different indicating the 
antagonist reliably shifted the agonist dose-response curve. 
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Results 
The average food intake for each dose of triazolam was plotted as a function 
of triazolam dose and revealed a peak intake of 197% at a dose of O .03 mg/kg ( see 
Figure 3). One-sample t-tests were performed to determine whether increases in food 
intake were significantly different from the control intake percentage of I 00. As seen 
in Table 2, the 0.03 mg/kg dose oftriazolam was reliably different from control levels 
(! (4)=2.197, g < .05). A one-way repeated measures analysis of variance revealed no 
significant difference among doses oftriazolam (E (4, 16)=1.22, g > 0.5). 
Average food intake following doses of zolpidem was also plotted as a 
function ofzolpidem dose and revealed a peak intake of292% at a dose of3.0 mg/kg 
(see Figure 4). One-sample t-tests revealed doses of zolpidem ranging from 1.0 
mg/kg to 10.0 mg/kg produced significant increases in intake relative to baseline (! 
(4)=3.274, IL< .05; 1 (4)=3.479, g,< .05; 1 (4)=3.302, g < .05, respectively). A one-
way repeated measures analysis of variance revealed a difference between doses of 
.zolpidem (E (4, 16)=7.24, g < .05). Fisher's post hoc analysis revealed that 1.0 
mg/kg, 3.0 mg/kg, and I 0.0 mg/kg doses of zolpidem yielded a significantly greater 
intake than the 0.03 mg/kg dose. Similarly, the 3.0 mg/kg and 10.0 mg/kg doses 
yielded a significantly greater intake than 17.8 mg/kg ofzolpidem. 
The average food intake for each dose of flumazenil and P-CCt were plotted 
as a function of dose and did not reveal a clear trend for an increase or decrease in 
intake as dose increased (see Figures 5 & 6). One-sample !-tests confirmed that doses 
of flumazenil ranging from 0.003 mg/kg to I 0.0 mg/kg and doses of P-CCt ranging 
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from 0.03 mg/kg to I 0.0 mg/kg did not yield a reliable difference from control levels 
(see Table 3). 
The average food intake following administration of each agonist alone and 
when combined with two doses of each antagonist were also plotted. Pre-treatment 
with both doses of flumazenil as well as both doses of ~-CCt with each agonist 
yielded dose-response functions that were shifted to the right in a largely parallel 
fashion (see Figures 7-10). To further assess these rightward shifts, ED50 values were 
generated for each animal under each drug condition (see Appendix). The mean ED50 
values for each agonist increased as doses of the antagonist increased (see Table 4). 
Dose ratios revealed the magnitude in which dose-response functions of 
agonists were shifted when combined with an antagonist (see Table 4). The co-
administration of0.03 mg/kg offlumazenil with various doses oftriazolam yielded a. 
dose ratio of3.9 (see Table 4, Figure 7). This dose ratio indicates that the ED50 of 
triazolam when in the presence of 0.03 mg/kg of flumazenil is approximately four 
times greater than the ED so of triazolam when administered alone. Triazolam co-
administered with 0.3 mg/kg offlumazenil yielded a dose ratio of 11.7, indicating that 
a 0.3 mg/kg dose offlumazenil shifted the dose-response function oftriazolam 11.7-
fold to the right. Similarly, 1.0 mg/kg of~-CCt engendered a 7.8-fold rightward shift 
when combined with triazolam (see Figure 8). 
The co-administration of flumazenil and ~-CCt with zolpidem produced 
comparable increases in dose ratios (Figures 9 & I 0). A dose of 0.03 mg/kg of 
flumazenil shifted the dose-response function ofzolpidem 5.0-fold to the right, while 
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0.3 mg/kg offlumazenil produced an 8.9-fold increase. The zolpidem dose-response 
function was shifted to the right by a magnitude of 4.6- and 5.4-fold in the presence 
of 1.0 mg/kg and 3.0 mg/kg of ~-CCt, respectively. All dose ratios described above 
were significant by comparison of 95% confidence intervals (see Table 4). 
Figure 3 
Food intake (Mean+ SEM) expressed as a percentage of control food intake plotted 
as a function oftriazolam dose. A one-sample t-test confirmed the 0.03 mg/kg dose 
of triazolam produced a significant increase in intake compared to control intake, 




"' -" ..... 0 * ... -" 0 u 200 ,_ 




0.001 0.01 0.1 
Triazolam Dose (mg/kg, i.m.) 
20 
Figure 4 
Food intake (Mean + SEM) expressed as a percentage of control food intake plotted 
as a function of zolpidem dose. * Denotes significant increases in food intake 
compared to control intake, assessed using one-sample t-tests. 
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Doses of triazolam and zolpidem produced significant increases in food intake 
compared to control food intake as assessed by one-sample !-tests. All analyses have 
4 degrees of freedom (critical !-value= 2.132, alpha= .05). 
Triazolam 
Dose (mg/kg) Mean SEM t p 
.003 81.408 47.478 -0.392 ns 
.01 155.403 37.551 1.475 ns 
.03 197.230 44.249 2.197 <.05 
.I 192.735 63.781 1.454 ns 
.3 108.678 58.693 0.148 ns 
Zolpidem 
Dose (mg/kg) Mean SEM t p 
.3 114.838 22.460 0.661 ns 
1.0 238.087 42.175 3.274 <.05 
3.0 292.198 55.238 3.479 <.05 
10.0 254.670 46.845 3.302 <.05 
17.8 175.558 38.753 1.949 ns 
Figure 5 
Food intake (Mean+ SEM) expressed as a percentage of control food intake plotted 
as a function of flumazenil dose. 
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Table 3 
Flumazenil and B-CCt did not reliably affect food intake when compared to control 
food intake as assessed by one-sample !-tests. All a_nalyses have 4 degrees of 
freedom (critical t-value = 2.776, alpha= .05). 
Flumazenil 
Dose (mg/kg) Mean SEM t p 
.003 91.511 23.103 -0.367 ns 
.01 93.973 41.867 -0. 144 ns 
.03 77.748 35.714 -0.623 ns 
.1 112.955 18.119 0.715 ns 
.3 151.465 33.389 1.541 ns 
1.0 112.494 27.743 0.450 ns 
3.0 150.329 22.699 2.217 ns 
10.0 117.815 37.291 0.478 ns 
~-CCt 
Dose (mg/kg) Mean SEM t p 
.03 83.063 6.646 -2.548 , ns 
.1 113.028 17.998 0.724 ns 
.3 81.761 31.410 -0.581 ns 
1.0 67.265 31.539 -1.038 ns 
3.0 118.435 15.433 1.195 ns 




Food intake (Mean+ SEM) following the co-administration oftriazolam with 0.03 
mg/kg and 0.3 mg/kg offlumazenil. 
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Figure 8 
Food intake (Mean+ SEM) following the co-administration oftriazolam with 1.0 
mg/kg and 3.0 mg/kg of B-CCt. 
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Figure 9 
Food intake (Mean+ SEM) following the co-administration of zolpidem with 0.03 
mg/kg and 0.3 mg/kg offlumazenil. 
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Figure 10 
Food intake (Mean+ SEM) following the co-administration ofzolpidem with 1.0 
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ED22 values (Mean±SEM) and dose ratios" calculated for each drug condition. The 
upper and lower limits of95% confidence intervals (CI) confirm doses offlumazenil 
and B-CCt reliably shifted the agonist dose-response function to the right. 
EDso SEM Dose Ratio Lower CI Upper CI 
Triazolam 0.014 0.002 1.0 1.0 1.0 
0.03 Flumazenil 0.042 0.009 3.9 2.9 4.9 
0 .3 Fl umazenil 0.146 0.038 11.7 8.9 14.4 
1.0 P-CCt 0.100 0.068 7.8 2.4 13.2 
Zolpidem 0.910 0.167 1.0 1.0 1.0 
0.03 Flumazenil 2.777 0.964 5.0 1.2 8.8 
0.3 Flumazenil 6.264 1.424 8.9 3.4 14.4 
1.0 P-CCt 3.893 1.680 4.6 3.6 5.6 
3.0 P-CCt 3.882 1.361 5.4 3.2 7.6 
• Dose ratios were calculated by dividing the ED so values of the agonist combined 
with the antagonist by the ED so value of the agonist alone. 
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Discussion 
Previous research has documented an increase in food intake following the 
administration of several nonselective benzodiazepine agonists (i.e., 
chlordiazepoxide, diazepam, midazolam) involving various species (see Table I). 
Consistent with these findings, the prototypical nonselective benzodiazepine agonist 
triazolam significantly increased the pellet intake of squirrel monkeys. An increase in 
food-maintained operant behavior has been reported for various benzodiazepine 
agonists in squirrel monkeys (Wettstein & Spealman, 1986); however, the present 
study measured hyperphagic effects more directly by evaluating pellet intake in non-
deprived monkeys, increasing external validity. The results of this thesis are also 
consistent with reports of nocturnal bingeing after triazolam use in people (Menkes, 
1992; Schenck et al., 1991 ). While triazolam nonselectively binds to benzodiazepine-
sensitive GABAA receptors, it may have greater efficacy than other conventional 
benzodiazepines (Ducic, Puia, Vicini, & Costa, I 993). Altogether, these findings 
suggest the possibility for increased side effects of triazolam compared to other 
benzodiazepines, perhaps due to relatively high effica~y at GABAA receptors. 
A dose-dependent increase in food intake was also found following 
administration of the GABAA/a.,-preferring agonist zolpidem. Other compounds with 
selectivity for GABAA/a,1 receptors, such as CL 218,872, zaleplon and quazepam, 
similarly increased food intake in rats and baboons (see Table !). However, research 
assessing the appetite stimulating effects ofzolpidem is inconsistent. Although an 
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increase in the number of pellets obtained under operant procedures used to evaluate 
the development of dependence and tolerance to zolpidem was documented (Griffiths 
et al., 1992; Weerts, Ator et al., 1998), other studies assessing the feeding behavior 
induced by zolpidem have reported no significant increase in food intake (Davies et 
al., 1994; Perrault et al., 1990; Sanger & Zivkovic, 1988; Y erbury & Cooper, 1989). 
It is important to note that the two studies reporting zolpidem-induced hyperphagia 
utilized non-human primates (Griffiths et al., 1992; Weerts, Ator et al., 1998), while 
others reporting no increase in intake following zolpidem administration involved the 
use ofrodents (Davies et al., 1994; Perrault et al., 1990; Sanger & Zivkovic, 1988; 
Yerbury & Cooper, I 989) suggesting that species differences may play a role in the 
inconsistent results with regard to zolpidem-induced hyperphagia. Species 
differences between non-human primates and rodents have previously been reported 
when assessing the behavioral effects of zolpidem. For example, research using 
baboons reported similarities between the discriminative stimulus effects of zolpidem 
and other benzodiazepines, while other studies using rats suggested discriminative 
stimulus effects of zolpidem were different from other benzodiazepines (reviewed in 
Griffiths et al., 1992; Rowlett & Woolverton, 1997). Further, tolerance to zolpidem 
has been documented in baboons, contrasting previous reports in which rats develop 
relatively less tolerance to zolpidem than other benzodiazepines. 
The nonselective benzodiazepine antagonist flumazenil did not significantly 
alter food intake when administered alone, consistent with previous reports (Cooper 
et al., 1985; Mansbach et al., 1984). However, flumazenil antagonized the 
• 
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hyperphagic effects oftriazolam and zolpidem in a surmountable fashion. Flumazenil 
has been found to antagonize hyperphagia and other behavioral effects associated 
with benzodiazepines when co-administered with triazolarn and zolpidem (Ator et al., 
2000; Davies et al., 1994; Reddy & Kulkarni, 1998; Rowlett & Woolverton, 1996; 
Sanger & Zivkovic, 1988). Similarly, diazepam- and CL 218,872-induced increases 
in food-maintained operant responding in squirrel monkeys were antagonized by 
flumazenil (Wettstein & Spealman, 1986). The surmountable antagonism of 
hyperphagia by flumazenil suggests that this effect is mediated by 
GABAA/benzodiazepine receptors. Because flumazenil is nonselective, it is unclear 
the extent to which binding to a single or multiple GABAA receptor subtypes are 
responsible for this effect. 
~-CC!, a GABAA/a1-preferring antagonist, did not significantly alter food 
intake when administered alone, consistent with previous research reporting no 
effects of this antagonism (Belzung, Le Guisquet, & Griebel, 2000; Lelas et al., 
2002). However, ~-CCt antagonized triazolam- and zolpidem-induced hyperphagia 
in a surmountable fashion. Because ~-CC! is approximate 20-fold selective for 
GABAA/a1 receptors compared to other GABAA receptor subtypes, these findings 
suggest that hyperphagia observed following zolpidem and triazolarn administration 
involved mechanisms mediated by GABAA/a, receptors. ~-CCt has not been shown 
previously to antagonize benzodiazepine-induced hyperphagia, but has reportedly 
blocked behavioral effects induced by zolpidem, as well as nonselective agonists. For 
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example, P-CCt antagonized zolpidem-induced, but not triazolam-induced distress 
vocalizations in mouse pups (Rowlett, et al., 2001). P-CCt also blocked the 
anticonvulsant and locomotor effects of zolpidem and diazepam (Griebel et al., 1999; 
Shannon et al., 1984). 
Researchers originally suggested the hyperphagic effect following 
administration ofbenzodiazepines was a consequence of reduced anxiety (reviewed 
in Pecina & Berridge, 1996). This theory was supported by studies reporting an 
increase in the intake of novel food compared to familiar chow (Johnson, 1978) and 
increased food intake in an unfamiliar environment (Britton & Britton, 198 I). That 
is, benzodiazepines purportedly relieved stress and anxiety produced by an unfamiliar 
environment and/or foods that normally would inhibit eating. However, subjects do 
not exhibit behaviors indicative of agitation or distress during saline control tests 
(Weerts, Macey, & Miczek, 1998). Moreover, benzodiazepine agonists have 
produced hyperphagia in non-stressful conditions (i.e., tested in homecages) and 
increased the intake of standard chow as well as novel food (Cooper & McClelland, 
1980; Griffiths et al., 1992; Kumar et al., 1999). Finally; agonists preferring 
GABAA/a.1 receptors, such as zolpidem and CL 218,872, relieve anxiety to a lesser 
degree than typical benzodiazepines, but show an increase in feeding, suggesting that 
a reduction of anxiety is not likely responsible for the hyperphagic effect (Mohler et 
al., 2002; Table 1 ). 
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Another hypothesis suggests that benzodiazepines activate mechanisms 
· related to feeding, possibly increasing appetite. Researchers supported this idea by 
reporting an increase in operant responding maintained by food delivery (i.e., Faltin 
et al., I 989). For example, benzodiazepines induced an increase in the rates of lever 
pressing to obtain food. In addition, benzodiazepine-induced hyperphagia has been 
documented in non-deprived, satiated animals (present results; see Table I). Taken 
together, these findings suggest that benzodiazepines increase appetite via stimulation 
ofGABAA receptors. 
As an alternative to changes in anxiety or appetite, Pecina and Berridge 
( I 996) have suggested that benzodiazepines enhance the palatability10 of food. 
Support for this hypothesis is provided by reports of a higher increase in average 
intake of preferred foods as well as bitter, non-preferred food engendered by 
benzodiazepines (Cooper & Moores, 1985; Berridge & Treit, 1986). Using a 
procedure that quantified species-typical reactions to aversive and pleasurable types 
of food, Berridge and Treit (1986) found that administration of chlordiazepoxide 
increased "favorable" responses to preferred food. However, negative responses to 
aversive foods were not decreased, suggesting benzodiazepines may only enhance the 
"positive evaluation" of preferred foods. Human research provides further evidence 
that benzodiazepines alter palatability. Compared to triazolam, subjects given the 
benzodiazepine agonist zopiclone reported an altered perception of taste, a side effect 
that subsided after administration was discontinued (Fleming, McClure, Mayes, 
Phillips, & Bourgouin, 1990). 
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While GABAA receptors are ubiquitous throughout the central nervous 
system, the receptors located in the brainstem may be responsible for the increase in 
palatability stimulated by benzodiazepines. Microinjections of diazepam delivered to 
the brainstem (via the fourth ventricle) ofrats significantly enhanced the palatability 
of food compared to microinjections of diazepam in the forebrain (via the lateral 
ventricles), suggesting GABAA receptors located in the brainstem may play a 
significant role in the observed hyperphagia (Pecina & Berridge, 1996). However, 
due to the widespread distribution of GABAA receptors in the nervous system, other 
brain regions may play a role in benzodiazepine-induced hyperphagia. 
The hypothalamus is a region in the mammalian brain directly related to 
feeding behavior and appetite (Kandel, Schwartz, & Jessel!, 2000). However, the 
distribution and density of GABAA/a, receptors in the hypothalamus are relatively 
low to moderate compared to other brain regions (Fritschy & Mohler, 1995). A low 
concentration of these receptors in the hypothalamus suggests an increase in 
palatability, rather than appetite per se, may contribute to benzodiazepine-induced 
hyperphagia. The sensation of taste originates in the taste buds, is projected through 
the medulla oblongata, where the sensation is consolidated in the solitary nuclear 
complex, projected to the thalamus and on to the cerebral cortex (Kandel et al., 1991 ). 
Consequently, GABAA/a1 receptors are found in the thalamus and throughout the 
cortex (Mohler et al., 2002). Diazepam injected into the fourth ventricle may have 
stimulated GABAA/a, receptors in the medulla oblongata affecting, altering 
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neurotransmission to the thalamus and cortex, resulting in an increase in palatability. 
Instead of direct infusions in specific brain regions, the present study administered 
benzodiazepines via systemic injections, activating benzodiazepine receptors in many 
brain regions, including the cerebral cortex. GABAA/a1 receptors in the cerebral 
cortex, in addition to the brainstem, may be related to the taste pathway and capable 
of altering palatability when stimulated. Other brain regions should be investigated 
for further evidence of this theory. 
Benzodiazepine-induced hyperphagia can potentially facilitate the 
understanding of the neural mechanisms of appetite and feeding behavior as well as 
mechanisms involved in the behavioral effects of benzodiazepines. A better 
understanding of this effect can lead to benzodiazepines that either avoid this side 
effect, or new compounds that use hyperphagia as a treatment in eating disorders. For 
example, compounds used to relieve anxiety may be developed that are devoid of this 
side effect via decreased selectivity and/or efficacy at GABAA/a1 receptors. In 
addition, terminally ill patients with decreased appetite or an altered sense of taste 
may benefit from benzodiazepines used to stimulate feeding behavior. 
Benzodiazepines selective for other GABAA receptor subunits should be assessed in 
similar experiments to further characterize the role of GABAA/a1 receptors in 
benzodiazepine-induced hyperphagia. For example, L-838,417 and SL 65 I ,498 are 
benzodiazepine agonists with selectivity for GABAA receptors containing the a 2, a 3, 
and as subunits, while QH-ii-66 is an agonist with selectivity for GABAA/a5 
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receptors (Greibel et al., 2001; Huang et al., 2000; McKeman et al., 2000). Research 
incorporating these selective compounds may provide further insight in understanding 
the specific roles of receptor subtypes in mediating the behavioral effects of 
benzodiazepines. 
In summary, triazolarn, a nonselective benzodiazepine agonist, and zolpidem, 
an agonist selective for GABAA/a:1 receptors, produced an increase in food intake in 
squirrel monkeys. The hyperphagic effect produced by both agonists was attenuated 
by flumazenil, a nonselective benzodiazepine antagonist, suggesting this effect is 
mediated by benzodiazepine receptors. Further, the hyperphagic effect produced by 
triazolam and zolpidem was also attenuated by the GABAA/a:1-preferring antagonist 
~-CCt. The present results suggest GABAA/a:1 receptors play a role in the 
hyperphagia observed after benzodiazepine administration. 
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Endnotes 
1 
"Sedative" refers to an agent that induces a state of reduced alertness, 
decreased motor activity and relaxation; a state of consciousness during which the 
individual experiences short bursts of sleep-)ike electrical activity in the brain but is 
neither asleep or aroused. Sedative-hypnotic drugs are used to promote sleep. 
2 
"Hypnotic" drugs induce a state of drowsiness leading to sleep from which 
the individual can be aroused. 
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3 
"Anxiolytics" are compounds used to relieve anxiety. Anxiety is defined as 
an unpleasant emotional state consisting of psychophysiological responses to 
anticipation of unreal or imagined danger and is applied to a cluster of symptoms: 
increased heart rate, alter_ed respiration rate, sweating, trembling, weakness and 
fatigue, feeling of impending danger, powerlessness, apprehension and tension. 
4 "Hyperphagia" is an increase in food intake. 
5 
An allosteric modulator is a compound ( e.g. benzodiazepine) that binds to a 
site on_ a receptor other than the neurotransmitter binding site. The compound can 
modify the activity of a receptor, or its affinity for its neurotransmitter. Allosteric 
modulators often do not have activity on their own. For example, the GABAA 
receptor is coupled with a chloride ion channel and has a binding site for GABA. 
However, it also has a separate binding site in which benzodiazepines bind. A 
benzodiazepine has no action alone, but in the presence of GABA, the agonist 
increases the frequency of which the er ion channel is opened, thus increasing the 
effect of GABA. 
6 Affinity refers to the degree of attraction for a drug at a n,ceptor site, while 
efficacy refers to the ability of a drug to produce the desired therapeutic effect. 
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7 Agonist generally refers to a drug with the ability to stimulate physiological 
activity at these receptors, similar to that produced by naturally occurring substances. 
A benzodiazepine agonist is a compound that binds to the benzodiazepine receptor 
site and enhances the electrophysiological effect of GABA. 
8 Antagonist generally refers to a drug that blocks or inhibits the effects of an 
agonist. Benzodiazepine antagonists are compounds that bind to the benzodiazepine 
receptor site with presumably no pharmacological effects when administered alone, 
but block the binding of pharmacologically active benzodiazepines to the receptor. 
9 Benzodiazepine inverse agonists are compounds that bind to the 
benzodiazepine site and decrease the frequency of chloride ion channel opening. 
Inverse agonists decrease the effects of GABA and can produce opposite effects of 
benzodiazepine agonists, such as convulsions, insomnia and anxiety. 
10 "Palatability" refers to a property or characteristic of food, denotes an 
agreeable or pleasurable taste. 
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Appendix A 
EDsa values were calculated for each animal in all drug conditions using the dose that 
produced the peak response. The EMAX value represents the maximum effect for the 
dose listed that produced the greatest increase in intake and is represented as a 
percentage of control intake. Isa is the percentage that corresponds to 50% of the 
maximum effect. ED so is the dose that corresponds to half of the maximum effect. 
Triazolam 
Subject Dose (mg/kg) EMAX¾ Isa% EDsa (mg/kg) 
89-94 0.03 209 154 0.02 
430-95 0.03 250 175 0.02 
450-95 0.1 432 266 0.02 
324-97 0.01 215 157 0.01 
89-99 0.01 130 115 0.01 
Triazolam + 0.03 Flumazenil 
Subject Dose (mg/kg) EMAx¾ Isa% EDsa (mg/kg) 
89-94 0.1 150 154 0.1 
430-95 0.1 241 175 0.1 
450-95 0.1 324 266 0.03 
324-97 0.03 168 157 0.02 
89-99 0.1 105 115 
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Triazolam + 0.3 Flumazenil 
Subject Dose (mg/kg) EMAX¾ Iso % EDso (mg/kg) 
430-95 0.3 219 175 0.2 
I 450-95 0.3 432 266 0.2 ~/ 324-97 0.1 192 157 0.1 
89-99 0.1 105 115 
Triazolam + 1.0 P-CCt 
Subject Dose (mg/kg) EMAX¾ Iso % EDso (mg/kg) 
430-95 0.3 206 175 0.2 ' 
450~95 0.3 194 266 
' t~ 
324-97 0.1 376 157 0.01 _.,,..,.....,, 
,89-99 0.1 151 115 0.1 
Triazolam + 3.0 P-CCt 
Subject Dose (mg/kg) EMAX¾ lso % EDso (mg/kg) 
430-95 0.3 156 175 
450-95 0.3 209 266 
324-97 0.3 145 157 
89-99 0.1 86. -115 
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Zo,lpidem 
Subject Dose (mg/kg) EMAX¾ lso % EDso (mgikg) 
430-95 3.0 -236 168 1.0 
450-95 3.0 490 295 0.7 
324-97 3.0 330 215 0.6 , 
89-99 . 10.0 228 164 1.4 
Zolpidem + 0.03 Flumazenil 
Subject Dose (mg/kg) EMAX¾ Iso % EDso (mg/kg) 
430-95 17.8 175 168 
" 450-95 17.8 533 295 2.6 
' 4 . .5 324-97 10.0 468' 215 
89-99 3.0 217 164 1.2 
Zolpidem + 0.3 Flumazenil 
Subject Dose (mg/kg) EMAX¾ Iso % EDso (mg/kg) 
430-95 10.0 241 168 4.9 
450-95 10.0 374 295 7.7 
324-97 10.0 430 215 
89-99 3.0 163 164 
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Zolpidem + 1.0 P-CCt 
Subject Dose (mg/kg) EMAX¾ lso % EDso (mg/kg) 
430-95 17.8 181 168 
450-95 10.0 432 295 2.2 
324-97 17.8 430 215 
89-99 10.0 203 164 5.6 
Zolpidem + 3.0 P-CCt 
Subject Dose (mg/kg) EMAx¾ lso % EDso (mg/kg) 
430-95 17.8 164 168 
450-95 3.0 403 295 1.6 
324-97 10.0 399 215 3.7 
89-99 10.0 198 164 6.3 
